Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective open-label study to evaluated the efficacy and safety of
infliximab(Remicade) in treating of patients with early ankylosing spondylitis (AS).
Infliximab was injected intra-venous on baseline, 2nd week, 6th week, 12th week and 24th
week, with dosing of 5mg/kg. The major outcome index is ASAS20, and minor outcome indexes
include ASAS50 and ASAS70, BASDAI20,BASDAI50 and BASDAI70. And MRI of sacroiliac joint is not
necessary. The adverse events at any time were recorded.